ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Net Interest Income (for Banks)

View and export this data going back to 1994. Start your Free Trial

What is ARIAD Pharmaceuticals Net Interest Income (for Banks)?

Net Interest Income only applies to banks.

ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARIAD Pharmaceuticals Inc (NAS:ARIA) » Definitions » Net Interest Income (for Banks)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.ariad.com

ARIAD Pharmaceuticals Inc was organized as a Delaware corporation in April 1991. It is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. The Company's first approved cancer medicine, Iclusig (ponatinib), and its product candidates, AP26113 and ridaforolimus, were discovered internally by its scientists based on the expertise in computational and structure-based drug design. AP26113 is an investigational inhibitor of anaplastic lymphoma kinase, or ALK. In non-clinical studies, AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. . Iclusig and its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that it has developed. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of Iclusig or its product candidates. The company's competitors includes pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.Inc.

Executives

Alexander J Denner	director	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Norbert G Riedel	director	BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Elona Esq. Kogan	officer: Sr. V. P. - General Counsel	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Manmeet Singh Soni	officer: EVP, CFO & Treasurer	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Timothy P Clackson	officer: President, R&D, CSO	C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jules Haimovitz	director	601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
Daniel M Bollag	officer: Sr. VP, Reg. Affairs & Quality	C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Hugh M Cole	officer: SVP, Chief Business Officer	C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
George Bickerstaff	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Paris Panayiotopoulos	director, officer: President and CEO	ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Anna Protopapas	director	MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Sarah J. Schlesinger	director	C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Massimo Radaelli	director	C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Martin J Duvall	officer: EVP, CCO	MGI PHARMA, INC., 5775 WEST OLD SHAKOPEE ROAD, SUITE 100, BLOOMINGTON MN 55437
Frank Haluska	officer: SVP, Clinical R&D, CMO	C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139